FDA gives Merck priority review for blood vessel disorder therapy sotatercept

[cafead]

via The Food and Drug Administration granted Merck priority review for its hypertension treatment sotatercept, following the results from the Phase 3 STELLAR trial, the company announced Thursday.

Sotatercept is a novel investigational activin signaling inhibitor targeting pulmonary arterial hypertension (PAH), a rare and progressive disease that causes the narrowing of blood vessels in the lungs.

article source